{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:42:51Z","timestamp":1784360571626,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.leukres.2021.106683","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T11:36:59Z","timestamp":1627990619000},"page":"106683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Proposal and clinical application of molecular genetic risk scoring system, \u201cMRplus\u201d, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-3425","authenticated-orcid":false,"given":"Sanjeev Kumar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-1644","authenticated-orcid":false,"given":"Vineet Kumar","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preity","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-5814","authenticated-orcid":false,"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10 October","key":"10.1016\/j.leukres.2021.106683_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.leukres.2021.106683_bib0010","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2021.106683_bib0015","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/10428194.2017.1408087","article-title":"Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection","volume":"59","author":"Gupta","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2021.106683_bib0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/leu.2010.275","article-title":"Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia","volume":"25","author":"Waanders","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106683_bib0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/pbc.24299","article-title":"Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR\/ABL-negative acute lymphoblastic leukemia","volume":"60","author":"Volejnikova","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.leukres.2021.106683_bib0030","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","article-title":"Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2021.106683_bib0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2021.106683_bib0040","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/leu.2010.87","article-title":"IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL","volume":"24","author":"Kuiper","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106683_bib0045","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.056135","article-title":"IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol","volume":"98","author":"Dorge","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106683_bib0050","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3324\/haematol.2012.075432","article-title":"What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia","volume":"98","author":"Palmi","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106683_bib0055","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bjh.13514","volume":"170","author":"Olsson","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.leukres.2021.106683_bib0060","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"van der Veer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106683_bib0065","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/leu.2013.92","article-title":"Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols","volume":"27","author":"Ofverholm","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106683_bib0070","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL consortium protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2021.106683_bib0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/leu.2015.199","article-title":"Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study","volume":"30","author":"Boer","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2021.106683_bib0080","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood-2014-03-562918","article-title":"A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia","volume":"124","author":"Moorman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106683_bib0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.leukres.2015.07.010","article-title":"IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: a prospective study from a tertiary care centre in Northern India","volume":"41","author":"Gupta","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2021.106683_bib0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.2517-6161.1968.tb00724.x","article-title":"A general definition of residuals","volume":"30","author":"Cox","year":"1968","journal-title":"J. R. Stat. Soc. Ser. B"},{"issue":"11 September","key":"10.1016\/j.leukres.2021.106683_bib0095","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2021.106683_bib0100","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41598-019-41078-4","article-title":"Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"9","author":"Steeghs","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2021.106683_bib0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/leu.2013.277","article-title":"An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions","volume":"28","author":"Clappier","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106683_bib0110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/leu.2013.282","article-title":"ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia","volume":"28","author":"Zaliova","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2021.106683_bib0115","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2013.085175","article-title":"Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features","volume":"98","author":"Schwab","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2021.106683_bib0120","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/10428194.2016.1193855","article-title":"Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia","volume":"58","author":"Gupta","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.leukres.2021.106683_bib0125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.leukres.2021.106683_bib0130","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","article-title":"IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia","volume":"30","author":"Moorman","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2021.106683_bib0135","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2021.106683_bib0140","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2021.106683_bib0145","doi-asserted-by":"crossref","first-page":"e27001","DOI":"10.1002\/pbc.27001","article-title":"Cyclin dependent kinase inhibitor 2A\/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia","volume":"65","author":"Agarwal","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.leukres.2021.106683_bib0150","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.15056","article-title":"A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children","volume":"180","author":"Sutton","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2021.106683_bib0155","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3324\/haematol.2018.204487","article-title":"ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity","volume":"104","author":"Zaliova","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2021.106683_bib0160","first-page":"1","article-title":"Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia","volume":"3","author":"Kastner","year":"2013","journal-title":"Am. J. Blood Res."},{"issue":"5","key":"10.1016\/j.leukres.2021.106683_bib0165","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ccell.2018.03.021","article-title":"Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia","volume":"33","author":"Churchman","year":"2018","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"10.1016\/j.leukres.2021.106683_bib0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7029","article-title":"Retrospective analysis of a novel molecular genetic risk score, \u201cMRplus\u201d, in BCR-ABL1 negative pediatric B-ALL: A single-center experience","volume":"39","author":"Gupta","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:37Z","timestamp":1758934897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"alternative-id":["S0145212621001843"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106683","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proposal and clinical application of molecular genetic risk scoring system, \u201cMRplus\u201d, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106683"}}